Brokerages Expect Eagle Pharmaceuticals Inc (EGRX) Will Post Quarterly Sales of $51.15 Million
Brokerages predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce $51.15 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $52.40 million and the lowest is $49.90 million. Eagle Pharmaceuticals reported sales of $46.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.3%. The firm is scheduled to report its next earnings report on Monday, February 25th.
On average, analysts expect that Eagle Pharmaceuticals will report full year sales of $208.40 million for the current fiscal year, with estimates ranging from $207.20 million to $209.60 million. For the next year, analysts anticipate that the business will post sales of $235.15 million, with estimates ranging from $219.80 million to $250.50 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. The business had revenue of $51.34 million for the quarter, compared to analysts’ expectations of $52.70 million. During the same period last year, the business earned $1.22 EPS. The business’s revenue was down 18.5% on a year-over-year basis.
NASDAQ EGRX opened at $47.13 on Friday. The firm has a market cap of $702.86 million, a PE ratio of 13.99 and a beta of 1.71. Eagle Pharmaceuticals has a one year low of $46.38 and a one year high of $85.66. The company has a current ratio of 5.59, a quick ratio of 5.38 and a debt-to-equity ratio of 0.20.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $108,000. Macquarie Group Ltd. lifted its stake in shares of Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,200 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $115,000. Piedmont Investment Advisors LLC bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at $150,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at $156,000.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Further Reading: How accurate is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.